A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson‐Viitanen, Iphigenia L. Koumenis, William Sun, Victor Sandor, Hagop M. Kantarjian

New England Journal of Medicine, 2012

The University of Texas MD Anderson Cancer Center, Mayo Clinic in Arizona, Cancer Prevention Institute of California, Stanford Cancer Institute, Incyte (United States), University of Toronto, Washington University in St. Louis, Frankston Hospital, Monash University, University of Utah, Huntsman Cancer Institute, Oregon Health & Science University, Cancer Institute (WIA), Saint Agnes Hospital, Cornell University, University of Michigan–Ann Arbor, Emory University, Duke University Health System, University of Pennsylvania, Presbyterian Medical Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2025

Citations

View on Google Scholar

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Abstract

Journal Details

Join JournalsHub

Welcome Back